India to United Arab Emirates: Amikacin Export Trade Route

To import Amikacin formulations into the UAE, the following approvals and registrations are mandatory:

The registration certificate is valid for five years from the date of approval. (mohap.gov.ae)

2. Local Authorized Representative: Foreign manufacturers must appoint a local authorized representative in the UAE. This representative is responsible for monitoring the product's safety and effectiveness post-launch and handling any product recalls or complaints. The local representative must be registered with MOHAP and may also serve as the product's distributor.

3. GMP Inspection Requirements: MOHAP mandates that manufacturing facilities comply with Good Manufacturing Practices (GMP). While specific inspection requirements for Indian facilities are not detailed, adherence to internationally recognized GMP standards is essential. Manufacturers should be prepared for potential inspections or audits by MOHAP to verify compliance.

Indian exporters of Amikacin formulations must meet the following quality and GMP standards to supply the UAE market:

1. GMP Certification: Manufacturing facilities must hold valid GMP certifications that align with international standards. Compliance with the World Health Organization's GMP guidelines is typically expected.

2. Approved Facilities: Specific information regarding Indian manufacturing facilities currently approved by MOHAP is not publicly available. Exporters should ensure their facilities meet all regulatory requirements and maintain open communication with MOHAP for approval status.

3. Regulatory Actions: As of November 2025, the Drugs Controller General of India (DCGI) has directed state authorities to enforce updated GMP standards strictly. Pharmaceutical companies failing to comply by December 31, 2025, face potential closure. This directive underscores the importance of GMP compliance for Indian exporters targeting markets like the UAE.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to the UAE:

1. GMP Compliance Deadline: In November 2025, the DCGI mandated that all pharmaceutical manufacturers in India comply with updated GMP standards by December 31, 2025. Non-compliance could result in operational shutdowns, affecting the ability to export to markets like the UAE.

2. Gulf Conflict Impact: In March 2026, escalating conflicts in the Gulf region disrupted Indian pharmaceutical exports. Shipping routes through the Persian Gulf and the Strait of Hormuz faced interruptions, leading to delays and increased costs for exporters. This situation has affected the timely delivery of pharmaceutical products, including Amikacin formulations, to the UAE.

Indian exporters must stay informed about these developments and ensure compliance with both Indian and UAE regulatory standards to maintain uninterrupted access to the UAE market.

Amikacin is a critical aminoglycoside antibiotic used primarily to treat severe bacterial infections, including those resistant to other antibiotics. In the United Arab Emirates (UAE), the demand for Amikacin formulations is influenced by several factors:

• Healthcare Spending: The UAE's healthcare expenditure has been steadily increasing, with a focus on enhancing medical infrastructure and services. This investment supports the availability and accessibility of essential medications like Amikacin.

• Disease Prevalence: The incidence of hospital-acquired infections and multidrug-resistant bacterial strains in the UAE necessitates the use of potent antibiotics such as Amikacin.

• Population Dynamics: An aging population and a growing number of expatriates contribute to a higher demand for comprehensive healthcare services, including effective antimicrobial treatments.

While specific market size data for Amikacin formulations in the UAE for 2024-2025 is not readily available, the country's reliance on imports for specialized pharmaceuticals indicates a significant market. Domestic manufacturing of Amikacin formulations is limited, making imports essential to meet the healthcare sector's needs.

The UAE adheres to the GCC Common Customs Law, which stipulates a standard import duty rate of 5% for most goods. However, pharmaceutical products classified under HS code 30049099, including finished Amikacin formulations, are exempt from import duties. This exemption aligns with the UAE's commitment to ensuring the availability of essential medicines.

In addition to import duties, the UAE imposes a Value Added Tax (VAT) of 5% on most goods and services. Pharmaceutical products, including Amikacin formulations, are subject to this VAT. Importers must also account for other charges such as customs clearance fees and administrative costs.

The Comprehensive Economic Partnership Agreement (CEPA) between India and the UAE, effective from May 2022, aims to enhance bilateral trade by reducing or eliminating tariffs on various products. Pharmaceuticals are among the sectors expected to benefit from this agreement, potentially facilitating smoother trade flows and reinforcing the UAE's position as a key market for Indian pharmaceutical exports.

India is a major supplier of Amikacin formulations to the UAE, accounting for approximately 5.3% of India's total Amikacin formulation exports, valued at $1.1 million USD across 57 shipments. The top Indian exporters include Chandra Bhagat Pharma Pvt Ltd, Pregen Exports (India), Medcell Pharma, Pozzo International, and Kwality Pharmaceuticals Limited.

Other countries, such as the United States and European Union member states, also export pharmaceutical products to the UAE. However, India's competitive pricing and established pharmaceutical manufacturing capabilities position it as a preferred supplier. The CEPA between India and the UAE further strengthens this trade relationship by potentially reducing trade barriers and enhancing market access.

While specific pricing data for Amikacin formulations from different countries is not publicly available, India's pharmaceutical industry is known for its cost-effective production methods. This efficiency allows Indian exporters to offer competitive prices compared to manufacturers from the EU and other regions, making Indian Amikacin formulations attractive to UAE importers seeking quality products at reasonable costs.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Amikacin, such as injections. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of November 2024, India had 376 facilities registered with the U.S. Food and Drug Administration (FDA), including 134 dedicated to finished dosage forms. Additionally, numerous Indian manufacturers hold World Health Organization Good Manufacturing Practice (WHO-GMP) certifications, ensuring compliance with international quality standards.

When comparing Amikacin formulations from India, China, and the European Union (EU), several factors emerge:

• Cost: Indian manufacturers offer Amikacin formulations at competitive prices due to lower production costs and economies of scale. Chinese products are also cost-effective but may face higher scrutiny regarding quality. EU-manufactured formulations are typically more expensive, reflecting higher production costs and stringent regulatory standards.

• Quality Perception: Indian pharmaceutical products are generally well-regarded for quality, especially those from WHO-GMP and FDA-approved facilities. Chinese products have faced quality concerns in certain markets, leading to cautious acceptance. EU products are perceived as high-quality due to strict regulatory oversight.

• Regulatory Acceptance in the UAE: The United Arab Emirates (UAE) recognizes and accepts products from WHO-GMP and FDA-approved facilities, facilitating the import of Indian Amikacin formulations. Chinese products may require additional scrutiny, while EU products are readily accepted due to established regulatory frameworks.

• Supply Reliability: Indian manufacturers have a strong track record of reliable supply, supported by robust infrastructure and experience in global distribution. Chinese suppliers have faced challenges related to regulatory compliance and quality issues, potentially affecting reliability. EU manufacturers offer reliable supply but at higher costs.

The India-UAE supply chain for Amikacin formulations is robust, underpinned by India's substantial manufacturing capacity and compliance with international quality standards. Indian facilities are equipped with advanced packaging and cold chain capabilities, ensuring the integrity of temperature-sensitive products like Amikacin injections. There have been no significant supply disruptions reported in recent years. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and FDA approvals. Leading manufacturers continue to expand their capacities to meet growing global demand, ensuring a steady supply of Amikacin formulations.

For UAE buyers sourcing Amikacin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple WHO-GMP and FDA-approved Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, commonly including letters of credit or advance payments, to build trust and ensure timely deliveries.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and quality assessments, to ensure compliance with UAE regulatory requirements.

• Regulatory Compliance: Verify that the selected suppliers have the necessary approvals and certifications recognized by UAE health authorities to facilitate smooth importation and distribution.

By adhering to this comprehensive framework, UAE companies can effectively qualify Indian suppliers of Amikacin formulations, ensuring compliance with regulatory standards and safeguarding public health.